Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Open accessThe DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 89 of the 278 sources its claims cite were checked for support.
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.
Overview
CoChat Summary
TL;DR
This overview applies Chouinard and Chouinard’s diagnostic criteria to withdrawal after decrease, discontinuation, or switch of psychotropic medications, distinguishing new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. It concludes that all reviewed drug classes may induce withdrawal and rebound even with slow tapering, but SSRIs, SNRIs, and antipsychotics are consistently associated with persistent post-withdrawal disorders and potentially high severity, whereas benzodiazepine discontinuation distress appears short-lived.
Key findings
- Withdrawal reactions can occur after abrupt discontinuation or gradual tapering; prevalence was reported as 54% among adults with serious mental illness, and antidepressant withdrawal incidence ranged from 27 to 86% (weighted average 56%). New withdrawal symptoms peak at 36–96 h, last up to 6 weeks, and are usually reversible; rebound symptoms return original symptoms at greater intensity; persistent post-withdrawal disorders last >6 weeks and are potentially irreversible.
- SSRIs, SNRIs, and antipsychotics were consistently associated with persistent post-withdrawal disorders and increased severity, including altered clinical course. Venlafaxine withdrawal rates ranged from 23 to 78%, and levomilnacipran from 9 to 10%. Antipsychotic supersensitivity psychosis prevalence was reported as 65% in a long-acting injectable risperidone study, 26.5% in a retrospective aripiprazole-switch study, and 72% in treatment-resistant schizophrenia patients treated with second-generation antipsychotics.
- Benzodiazepine new withdrawal symptoms are generally mild, transient, and subside within 2–4 weeks; 75% of patients withdrawn after long-term benzodiazepine use developed new withdrawal symptoms regardless of rapid or slow elimination. Rebound anxiety occurred in 5 of 7 (71.4%) bromazepam-treated patients versus 2 of 7 (28.6%) diazepam-treated patients. Persistent post-withdrawal disorders after long-term benzodiazepine use are described, but the literature is “hardly existent.”
- Ketamine and probably its derivatives may be classified as high risk for dependence and addiction; new withdrawal symptoms typically begin within 24 h, last approximately 3 days, and may persist for 2 weeks. Lithium withdrawal evidence is weak and ambiguous, and data on mood stabilizers are limited.
Methods
- Overview/review of the literature; MEDLINE was searched from inception to January 2020, with manual searching of reference lists and relevant reviews. Search terms combined “discontinuation/withdrawal” with drug-class terms (benzodiazepine, Z-drug, antidepressant, ketamine/esketamine, antipsychotic/neuroleptic, lithium, mood stabilizer).
- Eligible articles were English, peer-reviewed papers reporting data on adult subjects who decreased, discontinued, or switched psychotropic medications. Titles and abstracts were screened by 1 reviewer; potentially relevant full reports were independently assessed by 2 reviewers to consensus.
- Withdrawal symptoms were categorized using a previously used antidepressant discontinuation categorization (general, cardiovascular, gastrointestinal, genitourinary, sensory-related, neuromuscular, sexual, and central nervous system symptoms) and classified according to Chouinard and Chouinard’s criteria for new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders.
Limitations
- Stated: evidence for lithium withdrawal is weak and ambiguous; literature on persistent post-withdrawal disorders after long-term benzodiazepine use is hardly existent, and no studies were found on managing benzodiazepine persistent post-withdrawal disorders. No persistent post-withdrawal data are published for Z-drugs, and data are limited for newer antidepressants, carbamazepine, valproate, and lamotrigine; no rebound or persistent post-withdrawal data are available for mood stabilizers.
- Stated: proposed management strategies for SSRI/SNRI withdrawal—including hyperbolically decreasing dose patterns, multistep dose reduction, and Fava and Belaise’s pharmacological/non-pharmacological strategies—need testing in randomized controlled trials. One group CBT trial found only 37% (n = 26) discontinued antidepressants and 28% (n = 20) discontinued without recurrence, though timing and sample vulnerability may have contributed.
- Evident: this is a narrative overview rather than a systematic review or meta-analysis; no formal quality appraisal or risk-of-bias assessment is described, title/abstract screening was done by one reviewer, and conclusions often rely on case reports, online reports, and limited controlled data. The authors also note a lag phase between drug marketing and description of withdrawal symptoms, which limits certainty for newer agents.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Valid · 35 Not valid · 86 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This was confirmed by other studies [53-59].”
What the sources say
- Not checked — no full text of the sourcecites [53] source
- Not checked — no full text of the sourcecites [54] source
- Not checked — no full text of the sourcecites [55] source
- Not checked — no full text of the sourcecites [56] source
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Discussion (page not specified in our copy) says the study found no evidence of rebound insomnia after abrupt withdrawal of temazepam. Although this paper evaluated a short-term protocol, it does not confirm the attributed finding; it reports the opposite for the benzodiazepine it studied. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [58] source
- Disputedcites [59] sourceExperimental — accuracy not yet measured
The Design section describes nine nights of temazepam followed by three placebo recovery nights. Rather than confirming rebound insomnia after cessation, the Discussion (p. 695) says there was “no consistent disruption of sleep” and that mean sleep time during recovery was similar to baseline, although four of 12 patients had some disturbed recovery nights. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Recently, it has been described the case of a patient in which PSSD symptoms were part of a broader syndrome which was diagnosed as persistent post-withdrawal disorder [129].”
What the sources say
- Could not verifycites [129] sourceExperimental — accuracy not yet measured
The Discussion > Discontinuation symptoms passage concerns ketamine withdrawal, not PSSD or a diagnosis of persistent post-withdrawal disorder. Searches for those terms and for a patient case found no passage in our copy addressing the claimed case. (LLM, conf=0.76)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“One study found acute dystonia as new withdrawal symptom resulting from abrupt discontinuation of bupropion [105].”
What the sources say
- Could not verifycites [105] sourceExperimental — accuracy not yet measured
The Method and Results (pages unavailable) describe withdrawal reports involving SSRIs and SNRIs, not bupropion. A search for bupropion, acute dystonia, and movement disorders found no passage addressing the claimed symptom after abrupt bupropion discontinuation. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The evidence for withdrawal after lithium decrease or discontinuation is weak and ambiguous.”
What the sources say
- Could not verifycites [173] sourceExperimental — accuracy not yet measured
Section 2.1 mentions cognitive impairments with lithium and reports withdrawal reactions across psychotropic drugs, but does not assess the evidence for withdrawal specifically after lithium dose reduction or discontinuation. A search for lithium found no passage characterizing that evidence as weak or ambiguous; page numbers were unavailable in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
What the sources say
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [150] source
- Not checked — no full text of the sourcecites [151] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
91 more claims · 25 with their cited sources checked
Create a free account to see all 177 claims and every source verdict.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 56
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longer-term BZD use and use of high-dose, rapid-acting BZDs increase the risk of protracted withdrawal”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with other psychotropics, the potential for antidepressant PWS is embedded in pharmacodynamic adaptations and possibly irreversible neurophysiological alterations following prolonged drug exposure.19,20,31”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Untreated symptoms may be mild and resolve spontaneously in 1–3 weeks; in other cases they may persist for months or even years,40–45 leading to what has been defined as persistent post-withdrawal disorder.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–220 of 220
Is there a lamotrigine withdrawal syndrome?
Gelisse, P., Kissani, N., Crespel, A., Jafari, H., & Baldy-Moulinier, M. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.1c220.x · Cited by 10
Addressing Clinical Challenges of Antidepressant Discontinuation
Fava, G. A., & Cosci, F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18121419 · Cited by 10
Self-citationDiMascio, A., Dr, G., & Shader, R. I. (1968) · PubMed · Cited by 10
Patacchini, A., & Cosci, F. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001154 · Cited by 10
Self-citationMania: gender, transmitter function, and response to treatment
Swann, A. C., Petty, F., Bowden, C. L., Dilsaver, S. C., Calabrese, J. R., & Morris, D. D. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00069-4 · Cited by 9
Trazodone withdrawal and formication.
Ca, P. (1987) · PubMed · Cited by 8
Cosci, F. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2016.11.001 · Cited by 8
Self-citationHypomania following withdrawal of trazodone
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.11.1482b · Cited by 8
High-Dose Benzodiazepine Use among Long-Term Users: When Will We Ever Learn?
Zito, J. M. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437374 · Cited by 7
Long-Term Duloxetine Withdrawal Syndrome and Management in a Depressed Patient
Hou, Y., & Lai, C. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12110265 · Cited by 7
Benzodiazepines, antidepressants and addiction: A plea for conceptual rigor and consistency
Balon, R., Silberman, E. K., Starcevic, V., Cosci, F., Freire, R. C., Nardi, A. E., Rickels, K., & Shader, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119878171 · Cited by 7
Self-citationBehavioral Toxicity of Psychiatric Drugs
Perl, M., Hall, R. C. W., & Gardner, E. R. (1980) · Psychiatric Presentations of Medical Illness · doi:10.1007/978-94-011-7677-4_18 · Cited by 6
Frey, L. C., Strom, L. A., Shrestha, A., & Spitz, M. C. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2009.05.008 · Cited by 6
Behavioral toxicity of psychotropic drugs. V. Effects on gross behavior patterns.
DiMascio, A., Shader, R. I., & Gs, H. (1969) · PubMed · Cited by 6
Zolpidem-triggered seizures, depression, and reduced locomotion
Finsterer, J., & Frank, M. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.05.034 · Cited by 5
Panic Anxiety after Abrupt Discontinuation of Mianserin
Kuniyoshi, M., Arikawa, K., Miura, C., & Inanaga, K. (1989) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1989.tb02564.x · Cited by 4
Goldstein, J., & Macfadden, W. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106231.36344.f8 · Cited by 2
Seizures following the withdrawal of long-term treatment with mianserin
De Leo, D., Dalla Barba, G., & Zanchin, G. (1988) · The Italian Journal of Neurological Sciences · doi:10.1007/bf02337466 · Cited by 1
Fava, G. A., Gatti, A. M., Belaise, C., et al. (2015) · Figshare · doi:10.6084/m9.figshare.5127493
Fava, G. A., Benasi, G., Lucente, M., et al. (2018) · Figshare · doi:10.6084/m9.figshare.6825521
Cited by
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 95
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87
Metadata
- Authors
- Cosci, F., & Chouinard, G.
- Affiliations
- Maastricht University (NL)
- McGill University (CA)
- ORCID
- Cosci, Fiammetta
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 283-306
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3014423675
- Cited by
- 265
- References
- 219
- Citations by year
- 2026: 35 · 2025: 34 · 2024: 53 · 2023: 45 · 2022: 37 · 2021: 45 · 2020: 16
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- drug discontinuation, benzodiazepines, antidepressants, ketamine, antipsychotic drugs, lithium, mood stabilizers, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, quetiapine, drug addiction, children and adolescents
- MeSH terms
- Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.